

Shuai Xia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1387466/publications.pdf>

Version: 2024-02-01

47
papers

5,602
citations

218381

26
h-index

197535

49
g-index

50
all docs

50
docs citations

50
times ranked

10825
citing authors

#	ARTICLE	IF	CITATIONS
1	Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human I ² -Coronavirus Infection. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2809-2819.	2.9	9
2	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1652-1661.	5.7	24
3	Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. <i>Cell Research</i> , 2022, 32, 404-406.	5.7	31
4	A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern. <i>Viruses</i> , 2022, 14, 549.	1.5	13
5	Coronavirus Entry Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 101-121.	0.8	3
6	A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life. <i>Viruses</i> , 2022, 14, 655.	1.5	8
7	Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. <i>Nature Microbiology</i> , 2022, 7, 1063-1074.	5.9	63
8	Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection. <i>Microbes and Infection</i> , 2021, 23, 104840.	1.0	2
9	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 288.	7.1	38
10	Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 318.	7.1	7
11	Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. <i>Protein and Cell</i> , 2021, 12, 84-88.	4.8	31
12	25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11869.	1.8	16
13	Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha). <i>Cell Discovery</i> , 2021, 7, 109.	3.1	17
14	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 378.	7.1	26
15	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27141-27147.	3.3	173
16	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 282.	7.1	149
17	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. <i>JAMA Internal Medicine</i> , 2020, 180, 1356.	2.6	211
18	Identification of Human Single-Domain Antibodies against SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020, 27, 891-898.e5.	5.1	227

#	ARTICLE	IF	CITATIONS
19	The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 92.	7.1	263
20	An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	10
21	Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3843.	1.8	37
22	Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19. <i>Emerging Microbes and Infections</i> , 2020, 9, 1254-1258.	3.0	61
23	Development of oncolytic virotherapy: from genetic modification to combination therapy. <i>Frontiers of Medicine</i> , 2020, 14, 160-184.	1.5	40
24	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. <i>Cell Research</i> , 2020, 30, 343-355.	5.7	1,083
25	Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell. <i>ACS Infectious Diseases</i> , 2020, 6, 882-890.	1.8	14
26	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. <i>Emerging Microbes and Infections</i> , 2020, 9, 382-385.	3.0	1,086
27	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. <i>Cellular and Molecular Immunology</i> , 2020, 17, 765-767.	4.8	564
28	Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. <i>Virologica Sinica</i> , 2020, 35, 340-343.	1.2	10
29	A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. <i>Cellular and Molecular Immunology</i> , 2020, 17, 554-554.	4.8	124
30	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. <i>Science Advances</i> , 2019, 5, eaav4580.	4.7	393
31	Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator. <i>Viruses</i> , 2019, 11, 1064.	1.5	13
32	IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008082.	2.1	16
33	Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. <i>Viruses</i> , 2019, 11, 56.	1.5	31
34	Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD. <i>Viruses</i> , 2019, 11, 31.	1.5	20
35	Discovery of Hydrocarbon-Stapled Short α -Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2018-2026.	2.9	42
36	The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. <i>Frontiers in Microbiology</i> , 2018, 9, 2643.	1.5	29

#	ARTICLE	IF	CITATIONS
37	De Novo Design of α -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8734-8745.	2.9	41
38	Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. <i>International Journal of Molecular Sciences</i> , 2018, 19, 487.	1.8	63
39	Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	20
40	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. <i>Cell Host and Microbe</i> , 2017, 22, 471-483.e5.	5.1	48
41	Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. <i>Journal of Virology</i> , 2017, 91, .	1.5	25
42	Intranasal application of polyethyleneimine suppresses influenza virus infection in mice. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-2.	3.0	9
43	Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). <i>Emerging Microbes and Infections</i> , 2015, 4, 1-2.	3.0	11
44	Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. <i>Journal of Infectious Diseases</i> , 2015, 212, 1894-1903.	1.9	87
45	Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection. <i>Viruses</i> , 2015, 7, 798-819.	1.5	11
46	Testing of Middle East Respiratory Syndrome Coronavirus Replication Inhibitors for the Ability To Block Viral Entry. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 742-744.	1.4	41
47	Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. <i>Virus Research</i> , 2014, 194, 200-210.	1.1	100